Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Targeting IGF1R/Insr Pathway with Approved ALK-Inhibitors Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma

Max Alberto Mendez-Lopez, Andrej Besse, Tiberiu Totu, Marianne Kraus, Anthonius P.A. Janssen, Marija Buljan, Mario Van Der Stelt, Lenka Besse, Christoph Driessen

Blood (2023) 142 (Supplement 1): 4663.

https://doi.org/10.1182/blood-2023-177912

Published: 2023

Journal Articles

Bortezomib Resistant Multiple Myeloma Shows a Specific Dependency on Ecpas in Vitro and In Vivo

Lenka Besse, Andrej Besse, Sara C. Stolze, Amin Sobh, Marianne Kraus, Hirofumi Nakagami, Christoph Driessen

Blood (2022) 140 (Supplement 1): 4183–4184.

https://doi.org/10.1182/blood-2022-167648

Published: 2022

Journal Articles

Essential Drug Targets and Pathways in PI-Resistant MM Cells

Andrej Besse, Lenka Besse, Lorina Büchler, Sara C. Stolze, Amin Sobh, Marianne Kraus, Hirofumi Nakagami, Christoph Driessen

Blood (2021) 138 (Supplement 1): 1577.

https://doi.org/10.1182/blood-2021-150117

Published: 2021

Journal Articles

Effect of ABCB1 Multidrug Resistance Protein on Efficacy of Anti-Myeloma Drugs in Carfilzomib-Resistant Myeloma Model

Konstantin Byrgazov, PhD, Marianne Kraus, Andrej Besse, Ana Slipicevic, Fredrik Lehmann, Christoph Driessen, MD, Lenka Besse

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-136725

Published: 2020

Journal Articles

High Glutathione and NAD(P)H Levels, and Increased Protein Folding Capacity Are Involved in Mediating Proteasome Inhibitor-Resistance in Multiple Myeloma

Lenka Besse, Andrej Besse, Marianne Kraus, Jürgen Bader, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 1258.

https://doi.org/10.1182/blood.V130.Suppl_1.1258.1258

Published: 2017

Journal Articles

Defining the Most Effective Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors

Andrej Besse, Lenka Besse, Marianne Kraus, Juergen Bader, Gerjan de Bruin, Herman S Overkleeft, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 5388.

https://doi.org/10.1182/blood.V130.Suppl_1.5388.5388

Published: 2017

Journal Articles

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

Felicitas - Hitz, MD, Thomas - Pabst, MD, Dagmar - Hess, MD, Marianne Kraus, Lenka Besse, Urban Novak, MD, Katja - Seipel, MD, Stephanie - Rondeau, Silvia - Stüdeli, Simona Berardi, MD, Samaras Panagiotis, MD, Ulrich Mey, MD, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 1884.

https://doi.org/10.1182/blood.V130.Suppl_1.1884.1884

Published: 2017

Journal Articles

Nelfinavir Blocks Export of Newly Synthesized Protein from the ER and Interacts with ER-Resident and Mitochondrial Proteins in an Activity-Dependent Fashion

Andrej Besse, Lenka Besse, Sara C. Stolze, Marianne Kraus, Juergen Bader, Herman S Overkleeft, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 3074.

https://doi.org/10.1182/blood.V130.Suppl_1.3074.3074

Published: 2017

Journal Articles

The First in Class, Alkylator-Histone-Deacetylase-Inhibitor Fusion Molecule Edo-S101 in Combination with Proteasome Inhibitors Induces Highly Synergistic Pro-Apoptotic Signaling through UPR Activation and Suppression of c-Myc and BCL2 in Multiple Myeloma

Lenka Besse, PhD, Marianne Kraus, PhD, Andrej Besse, Juergen Bader, Thomas Mehrling, MD PhD, Christoph Driessen, MD PhD

Blood (2016) 128 (22): 4466.

https://doi.org/10.1182/blood.V128.22.4466.4466

Published: 2016

Journal Articles

Proteasome Inhibitor-Adapted Myeloma Cells That Lack Proteasome Gene Mutations Resist Highly Efficient Proteasome Inhibition and Show Proteomic Alterations That Suggest Complex Metabolic Changes

Lenka Besse, PhD, Guillem Soriano, Nan Li, Andrej Besse, Marianne Kraus, Juergen Bader, Tobias Christian Silzle, MD, Nico Meeuwenoord, Hans den Dulk, Herman S Overkleeft, Bogdan Florea, Christoph Driessen, MD

Blood (2015) 126 (23): 1278.

https://doi.org/10.1182/blood.V126.23.1278.1278

Published: 2015

Journal Articles

SAKK 65/08: A Phase I Dose Escalation Study of Bortezomib in Combination with Nelfinavir in Patients with Advanced Hematologic Malignancies

Christoph Driessen, MD, Jürgen Bader, Marianne Kraus, PhD, Markus Jörger, MD PhD, Hilde Rosing, PhD, Gregoire Berthod, MD, Felicitas Hitz, MD, Catherine Berset, PhD, Alexandros Xyrafas, Hanne Hawle, MD, Hermann S Overkleeft, PhD, Christiana Sessa, MD, Alwin Huitema, PhD, Ulrich JM Mey, Thomas Pabst, MD, Roger von Moos, MD, Dagmar Hess, MD

Blood (2014) 124 (21): 4747.

https://doi.org/10.1182/blood.V124.21.4747.4747

Published: 2014

Journal Articles

Edo- S101, a New Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Has Superior Activity Against Myeloma and B Cell Lymphoma and Strong Synergy with Proteasome Inhibitors in Vitro

Marianne Kraus, PhD, Jürgen Bader, Thomas Mehrling, MD PhD, Christoph Driessen, MD

Blood (2014) 124 (21): 2249.

https://doi.org/10.1182/blood.V124.21.2249.2249

Published: 2014

Journal Articles

SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity.

Christoph Driessen, MD, Dagmar Hess, MD, Thomas Pabst, MD, Sarah R Haile, Markus Joerger, MD, Roger von Moos, MD, Catherine Berset, Susanne Crowe, Hilde Rosing, PhD, Hermen S Overkleeft, Christiana Sessa, Marianne Kraus

Blood (2012) 120 (21): 2956.

https://doi.org/10.1182/blood.V120.21.2956.2956

Published: 2012

Journal Articles

Selective Inhibition of the proteasome's β2 Catalytic Subunit Alone Does Not Induce Cytotoxicity, but Resensitizes Bortezomib-Refractory Myeloma Cells for Bortezomib Treatment

Marianne Kraus, Bobby Florea, Jürgen Bader, Nan Li, Paul Geurink, Wouter van der Linden, Hermen S Overkleeft, Christoph Driessen, MD

Blood (2011) 118 (21): 2915.

https://doi.org/10.1182/blood.V118.21.2915.2915

Published: 2011

Journal Articles

The HIV Protease Inhibitor Nelfinavir: A Unique Oral Drug That Inhibits the Proteasome and AKT-Phosphorylation, Induces ER Stress and Sensitizes Bortezomib-Refractory Primary Myeloma Cells and Primary AML Cells towards Bortezomib

Christoph Driessen, MD, Jürgen Bader, Marianne Kraus

Blood (2010) 116 (21): 4069.

https://doi.org/10.1182/blood.V116.21.4069.4069

Published: 2010

Journal Articles

HIV-1–infected dendritic cells show 2 phases of gene expression changes, with lysosomal enzyme activity decreased during the second phase

Andrew N. Harman, Marianne Kraus, Chris R. Bye, Karen Byth, Stuart G. Turville, Owen Tang, Sarah K. Mercier, Najla Nasr, Josh L. Stern, Barry Slobedman, Christoph Driessen, Anthony L. Cunningham

Blood (2009) 114 (1): 85–94.

https://doi.org/10.1182/blood-2008-12-194845

Published: 2009

Includes: Supplemental data

Journal Articles

Secondary Bortezomib-Resistance Is Characterized by Upregulation of Proteasomal Subunits and Their Insufficient Inhibition by Bortezomib, Which Can Be Overcome by Alternative Proteasome Inhibitors Combined with Induction of the ER Stress Response.

Thomas Ruckrich, Jeannette Gogel, Marianne Kraus, Huib Ovaa, Christoph Driessen

Blood (2006) 108 (11): 2583.

https://doi.org/10.1182/blood.V108.11.2583.2583

Published: 2006

Journal Articles

Acquired Bortezomib (Velcade®)-Resistance Is Accompanied by Downmodulation of Proteasome Activity and Upregulation of Tripeptidyl Peptidase II (TPPII) and a Ubiquitin-Specific Protease.

Christoph Driessen, Jeanette Gogel, Marianne Kraus, Huib Ovaa, Alexander Beck, Thomas Rückrich

Blood (2005) 106 (11): 3375.

https://doi.org/10.1182/blood.V106.11.3375.3375

Published: 2005

Journal Articles

Activity Profiling of Proteasome Subunits and Deubiquitinating Enzymes in Human Hematopoetic Malignancies.

Christoph Driessen, Marianne Kraus, Jeanette Gogel, Alexander Beck, Winfried Kammer, Huib Ovaa, Herman Overkleeft, Thomas Rückrich

Blood (2005) 106 (11): 617.

https://doi.org/10.1182/blood.V106.11.617.617

Published: 2005

NARROW

Targeting IGF1R/Insr Pathway with Approved ALK-Inhibitors Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma

Bortezomib Resistant Multiple Myeloma Shows a Specific Dependency on Ecpas in Vitro and In Vivo

Essential Drug Targets and Pathways in PI-Resistant MM Cells

Effect of ABCB1 Multidrug Resistance Protein on Efficacy of Anti-Myeloma Drugs in Carfilzomib-Resistant Myeloma Model

High Glutathione and NAD(P)H Levels, and Increased Protein Folding Capacity Are Involved in Mediating Proteasome Inhibitor-Resistance in Multiple Myeloma

Defining the Most Effective Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

Nelfinavir Blocks Export of Newly Synthesized Protein from the ER and Interacts with ER-Resident and Mitochondrial Proteins in an Activity-Dependent Fashion

The First in Class, Alkylator-Histone-Deacetylase-Inhibitor Fusion Molecule Edo-S101 in Combination with Proteasome Inhibitors Induces Highly Synergistic Pro-Apoptotic Signaling through UPR Activation and Suppression of c-Myc and BCL2 in Multiple Myeloma

Proteasome Inhibitor-Adapted Myeloma Cells That Lack Proteasome Gene Mutations Resist Highly Efficient Proteasome Inhibition and Show Proteomic Alterations That Suggest Complex Metabolic Changes

SAKK 65/08: A Phase I Dose Escalation Study of Bortezomib in Combination with Nelfinavir in Patients with Advanced Hematologic Malignancies

Edo- S101, a New Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Has Superior Activity Against Myeloma and B Cell Lymphoma and Strong Synergy with Proteasome Inhibitors in Vitro

SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity.

Selective Inhibition of the proteasome's β2 Catalytic Subunit Alone Does Not Induce Cytotoxicity, but Resensitizes Bortezomib-Refractory Myeloma Cells for Bortezomib Treatment

The HIV Protease Inhibitor Nelfinavir: A Unique Oral Drug That Inhibits the Proteasome and AKT-Phosphorylation, Induces ER Stress and Sensitizes Bortezomib-Refractory Primary Myeloma Cells and Primary AML Cells towards Bortezomib

HIV-1–infected dendritic cells show 2 phases of gene expression changes, with lysosomal enzyme activity decreased during the second phase

Secondary Bortezomib-Resistance Is Characterized by Upregulation of Proteasomal Subunits and Their Insufficient Inhibition by Bortezomib, Which Can Be Overcome by Alternative Proteasome Inhibitors Combined with Induction of the ER Stress Response.

Acquired Bortezomib (Velcade®)-Resistance Is Accompanied by Downmodulation of Proteasome Activity and Upregulation of Tripeptidyl Peptidase II (TPPII) and a Ubiquitin-Specific Protease.

Activity Profiling of Proteasome Subunits and Deubiquitinating Enzymes in Human Hematopoetic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only